Umar Farooq, MD
Hematology & Oncology · Iowa City, IANPI 1336333673
Payments from drug & device makers
Across 262 payments — averaging $16,783 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- Genmab U.S., Inc.$1.2M
- Gilead$727K
- Janssen Research & Development, LLC$710K
- Regeneron$119K
- E.r. Squibb & Sons, L.L.C.$41K
- plus $30K from 5 others
Across 8 payments — averaging $177.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
- F. Hoffmann-la Roche AG$159
- Gilead$109
What the payments were for
- Consulting fees$27,03690%
- Travel & lodging$2,0807%
- Food & beverage$1,0543%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $1,537,951 |
| Genmab U.S., Inc. | 34 | $1,231,094 |
| Gilead | 125 | $727,178 |
| Janssen Research & Development, LLC | 62 | $710,295 |
| Regeneron | 17 | $119,358 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41,063 |
| Bristol Myers Squibb | 5 | $25,826 |
| Morphosys AG | 3 | $4,326 |
| Astellas Pharma US Inc | 3 | $56 |
| OPKO Pharmaceuticals, LLC | 1 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,397,225 in reported general payments places this provider in the 95th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 12 | $154,674 |
| VenclextaVenetoclax | 17 | $119,085 |
| EliquisApixaban | 32 | $18,379 |
| ValacyclovirValacyclovir Hcl | 20 | $1,913 |
| Acyclovir | 99 | $824 |
| Prochlorperazine Maleate | 39 | $461 |
| Gabapentin | 26 | $449 |
| Ondansetron Hcl | 48 | $337 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 42 | $178 |
| Prednisone | 62 | $154 |
| Duloxetine Hcl | 11 | $125 |
| Dexamethasone | 11 | $82 |
| Allopurinol | 24 | $32 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Iowa City
- Umang SwamiIowa City$9.7M
- Mohammed MilhemIowa City$6.4M
- Varun MongaIowa City$3.6M
- Douglas LauxIowa City$3.3M
- Christopher StrouseIowa City$2.3M
- Mark KarwalIowa City$2M
- George WeinerIowa City$840K
- Bilal RahimIowa City$527K
- Grerk SutamtewagulIowa City$468K
- Katarzyna JamiesonIowa City$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.